- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02343328
Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile Infection in Adults Using a Frozen Encapsulated Inoculum
September 12, 2017 updated by: Elizabeth L. Hohmann, MD, Massachusetts General Hospital
The investigators wish to compare Fecal Microbiota Transplant (FMT) capsules to placebo capsules in subjects with TWO episodes of C. difficile.
The investigators have numerous subjects and physicians requesting FMT at the time of a second relapse, in order to prevent further hospitalizations, obtain a faster and more durable cure, avoid costly medications like fidaxomicin and oral vancomycin, and "fix" the underlying dysbiosis.
In some instances, subjects feel like they are being asked to "get sick again" before they can pursue the most effective option.
The investigators propose to study these subjects with a rigorous placebo controlled design, which will contribute significantly to our understanding of the utility of FMT, timing, and the real relapse rates in a tertiary referral center.
Subjects who relapse with placebo will by definition have a third episode, meet consensus criteria for FMT, and will be offered "standard" FMT by capsule at that time.
Additionally, this study will allow us to further capture safety data, in comparison to placebo capsules and further enhance our understanding of the microbiology of dysbiosis, earlier on in the illness course.
Lastly, the investigators may decide to perform a cost analysis.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with two episodes of Clostridium dificile infection defined as having resolved symptoms after an initial microbiologically confirmed diagnosis of C. difficile, who have completed a course of antibiotics, and have a second positive test (toxin or PCR) obtained for a relapse of diarrhea symptoms by treating providers. Subjects with a positive "test of cure" stool sample (NOT advised by SHEA guidelines) in the absence of relapsed symptoms of CDI, or those who never improved their symptoms on the initial course of antibiotics will not be eligible. (Subjects who do not have a response to antibiotics may have other or additional diagnoses which are not likely to be helped by FMT.)
- Willingness to accept risk of unrelated donor stool.
- Age 18 or above. We do not believe there is a reason to have an upper age limit as long as patients can consent and can swallow large capsules. The elderly are disproportionately affected by CDI in terms of incidence, severity and affect on quality of life given limited mobility.
- Able to consent for self.
- Subjects are not expected to receive additional antibiotics for other indications in the next 8 weeks.
- Patients on a standard chemotherapeutic regimen for solid tumors, where significant duration of neutropenia is NOT expected in the 2 weeks following FMT may be enrolled with the agreement of their oncologist.
- Pt must be willing to have baseline Hepatitis B and C screening, and HIV screening (as required by the FDA for past studies). Those known to be seropositive for any of these illnesses need not be retested. These illnesses do not exclude subjects a priori, we simply wish to document initial sero-status.
- Subjects who have completed a second course of antibiotics may be enrolled up to 7 days after completing their second course of antibiotics for C. difficile
Exclusion Criteria:
- Delayed gastric emptying syndrome
- Known chronic aspiration
- Swallowing dysfunction or oral-motor dyscoordination, or inability or unwillingness to swallow multiple large capsules
- Pregnant women; we have previously and will continue to include postpartum and breastfeeding women. Women of child bearing potential have a urine or serum human chorionic gonadotropin test at enrollment.
- Patients with an acute illness unrelated to CDI or an acute exacerbation of underlying co-morbid condition
- Neutropenia (ANC <500) currently or expected within 2 weeks of FMT. (must have count within 7 d in relevant subjects, i.e. those with recent chemotherapy)
- Subjects on high dose steroids (>40 mg daily)
- Subjects on multiple/combination immunosuppressive regimens including high dose corticosteroids, calcineurin inhibitors, lymphocyte depleting biologic agents, anti-tumor necrosis factor agents. Subjects on a stable dose of a SINGLE immunosuppressive agent like steroids, rituximab, infliximab, other anti-TNF agents, with approval of the treating physician may be enrolled. These subjects may be at greatest risk of complications and hospitalization if another relapse of CDI occurs and may benefit.
- Patients with decompensated cirrhosis, advanced HIV/AIDS, recent bone marrow transplant, other cause of severe immunodeficiency.
- Patients with a history of significant allergy to foods not excluded from the donor diet (excluded foods are tree nuts, peanuts, shellfish, eggs)
- Ongoing systemic antibiotics for other infections (these people are better maintained on suppressive vancomycin and transplanted later). Subjects may have recently completed a course of antibiotics for another indication.
- Advanced HIV/AIDS with cluster of differentiation 4 cells (CD4) count less than 50.
- Allergy to chocolate/cocoa or gelatin, or unwillingness to ingest gelatin (in placebo capsules).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Fecal Microbiota Transplant Capsules
Fecal microbiota transplant capsules
|
|
PLACEBO_COMPARATOR: Placebo Capsules
Placebo capsules made from a mixture of natural cocoa powder and gelatin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resolution of diarrhea/Clostridium dificile infection symptoms and/or no relapse of C.difficile at 8 weeks
Time Frame: 8 weeks
|
The primary objective of this study is to evaluate the safety and efficacy of FMT, and the relapse rate compared to placebo at 8 weeks, with cure defined by the absence of diarrhea/CDI symptoms at 8 weeks.
We are defining the absence of relapsed CDI at 8 weeks symptoms as a cure.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Self-reported weight
Time Frame: Over 6 months
|
Over 6 months
|
Subjective well-being/improvement per standardized health rating scales (general health and GI health; as described above and on CRF).
Time Frame: Over 6 months
|
Over 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (ACTUAL)
July 29, 2016
Study Completion (ACTUAL)
July 29, 2016
Study Registration Dates
First Submitted
January 15, 2015
First Submitted That Met QC Criteria
January 21, 2015
First Posted (ESTIMATE)
January 22, 2015
Study Record Updates
Last Update Posted (ACTUAL)
September 13, 2017
Last Update Submitted That Met QC Criteria
September 12, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014P002706
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridium Difficile
-
Vedanta Biosciences, Inc.CompletedClostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection RecurrenceUnited States, Canada
-
DeinoveRecruitingClostridium Difficile (C. Difficile)United States, Canada
-
Hamilton Health Sciences CorporationRecruitingClostridium Difficile Diarrhea | Clostridium Difficile ColonizationCanada
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
Microbiome Health Research InstituteBrown University; Tufts Medical Center; Indiana University; Edward HospitalTerminatedClostridium DifficileUnited States
-
Seres Therapeutics, Inc.Syneos HealthCompletedClostridium DifficileUnited States
-
University of AlbertaTerminatedClostridium DifficileCanada
-
McMaster UniversitySt. Joseph's Healthcare HamiltonTerminated
-
Astellas Pharma Europe Ltd.Merck Sharp & Dohme LLCCompletedClostridium DifficileGreece, Spain, Russian Federation, Denmark, Austria, Belgium, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania, Slovenia, Sweden, Switzerland, Turkey, United Kingdom
-
University of Wisconsin, MadisonAgency for Healthcare Research and Quality (AHRQ)Enrolling by invitationClostridium Difficile Infection | Clostridium Difficile | C Difficile ColitisUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States